FILE - This Oct. 10, 2013, file photo, shows an EpiPen epinephrine auto-injector, a Mylan product, in Hendersonville, Texas. Some big pension funds are urging shareholders of EpiPen maker Mylan to reject several company directors and the compensation it gives top executives, including the nearly $100 million Chairman and former CEO Robert Coury received last year. The pension funds say that the compensation came during backlash over prices the drugmaker charged for its EpiPen emergency allergy treatment. They also note that the company agreed to make “extraordinary and egregious” payments last year and over the next five years to Coury.(AP Photo/Mark Zaleski, File)
Featured Photo Galleries
